These findings are consistent with prior ITP studies demonstrating that insurance status significantly impacts access to advanced therapies, such as thrombopoietin receptor agonists and specialist consultations, ultimately influencing clinical outcomes [14]. The gene discussed is MPL; the disease is autoimmune thrombocytopenic purpura.